Glimcher Named Dana-Farber President
Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of Dana-Farber Cancer Institute. Dr. Glimcher is currently the Stephen and Suzanne Weiss Dean of the Medical College at Weill Cornell Medicine in New York City, where she is also professor of medicine and provost for medical affairs at Cornell University. Dr. Glimcher will begin at Dana-Farber in January 2017, and current President Edward J. Benz, Jr., MD, has agreed to remain as president until her arrival.
"Dr. Glimcher is in many ways an ideal choice for Dana-Farber," said Josh Bekenstein, chairman of the Dana-Farber Board of Trustees. "She is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. She has had extraordinary success as the leader of a major academic medical institution. Most importantly, she has a deep understanding of the latest developments in cancer research and care, and a clear vision of how Dana-Farber can most powerfully affect the fight against cancer."
The Dana-Farber CEO plays a important role across the Harvard University-affiliated health sciences organizations, and Glimcher will serve as president of Dana-Farber/Partners Cancer Care, principal investigator of Dana-Farber/Harvard Cancer Center, and trustee of Dana-Farber/Boston Children’s Hospital Cancer Care.